Opus Genetics (NASDAQ:IRD) Posts Quarterly Earnings Results, Misses Expectations By $0.59 EPS

Posted by Stanley Muller on May 12th, 2026

Opus Genetics (NASDAQ:IRD – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.59), Zacks reports. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 349.33%.

Opus Genetics Stock Performance

Shares of Opus Genetics stock traded down $0.05 during mid-day trading on Tuesday, hitting $5.07. 871,467 shares of the stock were exchanged, compared to its average volume of 900,419. Opus Genetics has a 12 month low of $0.90 and a 12 month high of $5.81. The company has a 50-day simple moving average of $4.94 and a 200 day simple moving average of $3.26. The company has a market capitalization of $362.28 million, a P/E ratio of -6.19 and a beta of 0.62.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on IRD shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Opus Genetics in a research report on Tuesday, April 21st. Citigroup assumed coverage on Opus Genetics in a report on Tuesday, April 28th. They issued an “outperform” rating on the stock. B. Riley Financial restated a “buy” rating on shares of Opus Genetics in a report on Thursday, April 30th. Oppenheimer assumed coverage on Opus Genetics in a report on Monday, March 16th. They issued an “outperform” rating and a $10.00 target price on the stock. Finally, Wedbush raised their target price on Opus Genetics from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.30.

Check Out Our Latest Stock Analysis on IRD

Insider Activity

In other Opus Genetics news, insider Ashwath Jayagopal sold 7,542 shares of Opus Genetics stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $5.19, for a total transaction of $39,142.98. Following the transaction, the insider owned 509,233 shares of the company’s stock, valued at $2,642,919.27. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO George Magrath sold 24,438 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $5.21, for a total value of $127,321.98. Following the completion of the transaction, the chief executive officer owned 1,750,855 shares of the company’s stock, valued at $9,121,954.55. This trade represents a 1.38% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 73,395 shares of company stock worth $382,278 in the last quarter. 11.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Nantahala Capital Management LLC raised its position in Opus Genetics by 42.9% in the fourth quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock worth $9,610,000 after acquiring an additional 1,435,407 shares during the period. Balyasny Asset Management L.P. bought a new stake in Opus Genetics in the fourth quarter worth about $5,463,000. Millennium Management LLC bought a new stake in Opus Genetics in the fourth quarter worth about $4,025,000. Mink Brook Asset Management LLC grew its holdings in Opus Genetics by 34.5% during the fourth quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock valued at $3,348,000 after purchasing an additional 427,684 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Opus Genetics by 35.3% during the third quarter. Vanguard Group Inc. now owns 1,342,025 shares of the company’s stock valued at $2,214,000 after purchasing an additional 349,825 shares during the period. Institutional investors own 14.97% of the company’s stock.

About Opus Genetics

(Get Free Report)

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.